Discontinuing Antidepressant Drugs: Lesson from a Failed Trial and Extensive Clinical Experience
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Persistent post-withdrawal disorders, defined as rebound symptoms and/or new withdrawal symptoms and/or emerging new psychotic symptoms of another type persisting longer than 6 weeks, have been described after discontinuation of antipsychotics.
“Persistent post-withdrawal disorders, that is a condition in which rebound symptoms and/or new withdrawal symptoms and/or emerging new psychotic symptoms of another type, such as disorganized behavior, persist longer than 6 weeks, have been described after discontinuation of antipsychotics.”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [22]
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measuredPersistent post-withdrawal supersensitivity psychosis is characterized by rebound and/or new withdrawal psychosis after decrease, discontinuation, or switch of antipsychotics, associated with rapid appearance or reappearance of positive symptoms and emergence of a definite drug-induced movement disorder.
“Persistent post-withdrawal supersensitivity psychosis is characterized by rebound and/or new withdrawal psychosis occurring after decrease, discontinuation, or switch of antipsychotics which is associated with rapid appearance or reappearance of positive symptoms (i.e., illusion, hallucination, catatonia, Schneider passivity experience, delusion) and with the emergence of one definite drug-induced”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [22]
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measuredChouinard et al. concluded that 2 persistent post-withdrawal disorders, tardive dyskinesia and supersensitivity psychosis, were specifically induced by antipsychotics.
“and that 2 persistent post-withdrawal disorders, tardive dyskinesia and supersensitivity psychosis, were specifically induced by antipsychotics [21, 22, 150, 151].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [22]
The References section lists a Chouinard et al. paper titled “Antipsychotic-induced dopamine supersensitivity psychosis,” supporting the antipsychotic association for one named condition. The discussion of persistent postwithdrawal disorder in “The Role of Assessment in Planning Drug Discontinuation” does not identify tardive dyskinesia or supersensitivity psychosis as the two disorders, so the full conclusion is not supported by this copy. (LLM, conf=0.76)
Experimental — accuracy not yet measuredOur review's main finding reflects the poor recognition and insufficient consideration of PAWS in both clinical research and practice.
“Our review’s main finding thus reflects the poor recognition and insufficient consideration of PAWS in both clinical research and practice (Cosci et al., 2024; Fava and Belaise, 2018; Horowitz and Davies, 2025; Read et al., 2023).”
From Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis (2025) · cites this paper as Fava and Belaise, 2018
Compared to the steadily increasing number of editorials, commentaries and narrative reviews mentioning PAWS, the lack of high-quality original studies providing reliable evidence on the epidemiology and clinical management of PAWS is striking.
“Nevertheless, compared to the steadily increasing number of editorials, commentaries and narrative reviews mentioning PAWS (e.g. Chouinard and Chouinard, 2015; Davies et al., 2019; Fava and Belaise, 2018; Fava and Cosci, 2019; Lerner and Klein, 2019), the lack of high-quality original studies providing reliable evidence on the epidemiology and clinical management of PAWS is striking.”
From Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis (2025) · cites this paper as Fava and Belaise, 2018
A protocol based on the sequential combination of CBT and WBT in post-withdrawal disorders has been devised and tested in case reports.
“A protocol based on the sequential combination of CBT and WBT in post-withdrawal disorders has been devised 101 and tested in case reports 102 .”
From The pursuit of euthymia (2020) · cites this paper as [101]
Two specific persistent post-withdrawal disorders, persistent post-withdrawal tardive dyskinesia and persistent post-withdrawal supersensitivity psychosis, have been well described.
“2 specific persistent post-withdrawal disorders, named persistent post-withdrawal tardive dyskinesia and persistent post-withdrawal supersensitivity psychosis, have been well described [21, 22, 150, 151].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [22]
The Role of Assessment in Planning Drug Discontinuation defines persistent postwithdrawal disorder generally, but does not identify tardive dyskinesia or supersensitivity psychosis as forms of it. Searches for both disorder names found no passage describing them; supersensitivity psychosis appears only in a reference title. Page numbers were unavailable in our copy. (LLM, conf=0.76)
Experimental — accuracy not yet measuredA few authors have suggested that reinstating the drug may be detrimental and lead to more severe withdrawal.
“However, this recommendation is not supported by controlled data, and a few authors even suggested that reinstating the drug may be detrimental and lead to more severe withdrawal.39,45”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [45]
The recommendation to reinstate the drug in acute antidepressant withdrawal is not supported by controlled data.
“However, this recommendation is not supported by controlled data, and a few authors even suggested that reinstating the drug may be detrimental and lead to more severe withdrawal.39,45”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [45]
Withdrawal symptoms are likely to be misunderstood as indications of relapse and may lead to starting treatment with AD again, perpetuating the problem.
“Withdrawal symptoms are likely to be misunderstood as indications of relapse and may lead to starting treatment with AD again, perpetuating the problem.”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [50]
Withdrawal symptoms after stopping psychotropic drugs are a form of behavioral toxicity.
“Withdrawal symptoms, which may follow discontinuation of psychotropic drugs, such as benzodiazepines [36], antipsychotic medications [4,37], and antidepressant treatment [38][39][40], are also a form of behavioral toxicity.”
From Iatrogenic Factors in Psychopathology (2019) · cites this paper as [36]
A particular form of resistance occurs when a drug that produced clinical response in previous episodes is no longer effective when restarted after a drug-free period.
“A particular form of resistance occurs when a drug which resulted in clinical response in previous episodes is no longer effective when it is started again after a drug-free period.”
From The Deceptive Manifestations of Treatment Resistance in Depression: A New Look at the Problem (2020) · cites this paper as [26]
Increasing antidepressant dosage may yield only temporary improvement.
“Increase in dosage may only yield temporary improvement [26].”
From The Deceptive Manifestations of Treatment Resistance in Depression: A New Look at the Problem (2020) · cites this paper as [26]
Improvement may result from antidepressant discontinuation.
“Improvement may result from antidepressant discontinuation [26].”
From The Deceptive Manifestations of Treatment Resistance in Depression: A New Look at the Problem (2020) · cites this paper as [26]
Antidepressant use may be associated with paradoxical effects: new symptoms and exacerbation of baseline clinical picture, in addition to loss of clinical effect.
“Use of antidepressants may be associated not only with the return of depressive symptoms during maintenance treatment (loss of clinical effect), but also with the appearance of new symptoms and exacerbation of baseline clinical picture (paradoxical effects).”
From The Deceptive Manifestations of Treatment Resistance in Depression: A New Look at the Problem (2020) · cites this paper as [26]
Resistance may ensue with loss of clinical effect in a patient who previously responded to antidepressant drug treatment.
“Resistance may also ensue with loss of clinical effect in a patient who previously responded to antidepressant drug treatment.”
From The Deceptive Manifestations of Treatment Resistance in Depression: A New Look at the Problem (2020) · cites this paper as [26]
Resistance to re-challenge, loss of clinical effects, paradoxical reactions, withdrawal and postwithdrawal syndromes tend to cluster and may share a common mechanism subsumed under the oppositional model of tolerance.
“Resistance to re-challenge, loss of clinical effects, paradoxical reactions, withdrawal and postwithdrawal syndromes tend to cluster and may share a common mechanism that has been subsumed under the rubric of oppositional model of tolerance [26, 32].”
From The Deceptive Manifestations of Treatment Resistance in Depression: A New Look at the Problem (2020) · cites this paper as [26]
The return of depressive symptoms during maintenance antidepressant treatment occurs in a significant proportion of patients in published trials.
“The return of depressive symptoms during maintenance antidepressant treatment was found to occur in a significant proportion of patients in published trials [26, 28].”
From The Deceptive Manifestations of Treatment Resistance in Depression: A New Look at the Problem (2020) · cites this paper as [26]
The prevalence of resistance to re-challenge varies but may occur in up to one third of patients.
“The prevalence of this type of resistance varies but may occur in up to one third of patients [26, 27].”
From The Deceptive Manifestations of Treatment Resistance in Depression: A New Look at the Problem (2020) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Cognitive Therapy for Depression
(2012) · PsycEXTRA Dataset · doi:10.1037/e675542012-001 · Cited by 9,678 · see citing works
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945 · see citing works
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574 · see citing works
(2009) · Cited by 407 · see citing works
Long-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332 · see citing works
(2004) · PubMed · Cited by 296 · see citing works
Antidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286 · see citing works
Cognitive behavioral treatment of residual symptoms in primary major depressive disorder
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.9.1295 · Cited by 266 · see citing works
Self-citationCan long-term treatment with antidepressant drugs worsen the course of depression?
Fava, G. A. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0204 · Cited by 223 · see citing works
Self-citationFava, G. A., Benasi, G., Lucente, M., Offidani, E., Cosci, F., & Guidi, J. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491524 · Cited by 209 · see citing works
Self-citationThe clinical interview for depression
Paykel, E. S. (1985) · Journal of Affective Disorders · doi:10.1016/0165-0327(85)90014-x · Cited by 187 · see citing works
Well-Being Therapy: Treatment Manual and Clinical Applications
Fava, G. A. (2016) · doi:10.1159/isbn.978-3-318-05822-2 · Cited by 170 · see citing works
Self-citationGuidi, J., Tomba, E., & Fava, G. A. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040476 · Cited by 167 · see citing works
Self-citationNew Classification of Selective Serotonin Reuptake Inhibitor Withdrawal
Chouinard, G., & Chouinard, V.-A. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000371865 · Cited by 164 · see citing works
Clinically Significant Drug Interactions with Newer Antidepressants
Spina, E., Trifirò, G., & Caraci, F. (2011) · CNS Drugs · doi:10.2165/11594710-000000000-00000 · Cited by 160 · see citing works
Antidepressant discontinuation syndromes
Haddad, P. M., Anderson, I. M., & Rosenbaum, J. F. (2004) · Oxford University Press eBooks · doi:10.1093/med/9780198527480.003.0010 · Cited by 160 · see citing works
The mechanisms of tolerance in antidepressant action
Fava, G. A., & Offidani, E. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.026 · Cited by 158 · see citing works
Self-citationLong-term outcome of panic disorder with agoraphobia treated by exposure
FAVA, G. A., RAFANELLI, C., GRANDI, S., CONTI, S., RUINI, C., MANGELLI, L., & BELLUARDO, P. (2001) · Psychological Medicine · doi:10.1017/s0033291701003592 · Cited by 156 · see citing works
Self-citationAntidepressant discontinuation: a review of the literature.
Lejoyeux, M., & Adès, J. (1997) · PubMed · Cited by 135 · see citing works
Antidepressant Discontinuation Syndrome
Brink, C. B., & Brand, L. (2017) · The SAGE Encyclopedia of Abnormal and Clinical Psychology · doi:10.4135/9781483365817.n77 · Cited by 134 · see citing works
Tint, A., Haddad, P. M., & Anderson, I. M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107081550 · Cited by 114 · see citing works
Nielsen, M., Hansen, E. H., & Gøtzsche, P. C. (2012) · Addiction · doi:10.1111/j.1360-0443.2011.03686.x · Cited by 103 · see citing works
A review of the management of antidepressant discontinuation symptoms
Wilson, E., & Lader, M. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125315612334 · Cited by 103 · see citing works
Well-Being Therapy: Current Indications and Emerging Perspectives
Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000444114 · Cited by 96 · see citing works
Self-citationRational Use of Antidepressant Drugs
Fava, G. A. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000362803 · Cited by 95 · see citing works
Self-citationFava, G. A., Bernardi, M., Tomba, E., & Rafanelli, C. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706007462 · Cited by 80 · see citing works
Self-citationUse of the Psychosocial Index: A Sensitive Tool in Research and Practice
Piolanti, A., Offidani, E., Guidi, J., Gostoli, S., Fava, G. A., & Sonino, N. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447760 · Cited by 79 · see citing works
Self-citationBenzodiazepines as a monotherapy in depressive disorders: a systematic review
Benasi, G., Guidi, J., Offidani, E., Balon, R., Rickels, K., & Fava, G. A. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000486696 · Cited by 79 · see citing works
Schatzberg, A. F., Blier, P., Delgado, P. L., D, M. F. M., Haddad, P. M., & Shelton, R. C. (2006) · PubMed · Cited by 78 · see citing works
Evidence-based medicine was bound to fail: a report to Alvan Feinstein
Fava, G. A. (2017) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2017.01.012 · Cited by 74 · see citing works
Self-citationExplanatory Therapy in Hypochondriasis
Fava, G. A., Grandi, S., Rafanelli, C., Fabbri, S., & Cazzaro, M. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0414 · Cited by 73 · see citing works
Self-citationHuijbregts, K. M. L., Hoogendoorn, A. W., Slottje, P., van Balkom, A. J. L. M., & Batelaan, N. M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000480456 · Cited by 67 · see citing works
Cloos, J.-M., Bocquet, V., Rolland-Portal, I., Koch, P., & Chouinard, G. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000434755 · Cited by 57 · see citing works
Behavioral Toxicity Revisited: Iatrogenic Comorbidity in Psychiatric Evaluation and Treatment
Fava, G. A., Cosci, F., Offidani, E., & Guidi, J. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000570 · Cited by 55 · see citing works
Self-citationAssessing medication burden and polypharmacy: finding the perfect measure
Gnjidic, D., Tinetti, M., & Allore, H. G. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1301206 · Cited by 54 · see citing works
Depression Associated with Medical Illness: Treatment Considerations
Fava, G. A., & Sonino, N. (1996) · CNS Drugs · doi:10.2165/00023210-199605030-00004 · Cited by 53 · see citing works
Self-citationGhaemi, S. N. (2002) · doi:10.1201/b15278 · Cited by 48 · see citing works
Withdrawal Syndromes After Paroxetine and Sertraline Discontinuation
Fava, G. A., & Grandi, S. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199510000-00012 · Cited by 46 · see citing works
Self-citationBelaise, C., Gatti, A., Chouinard, V.-A., & Chouinard, G. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000362317 · Cited by 44 · see citing works
Self-citationGrace, S. L., Medina-Inojosa, J. R., Thomas, R. J., Krause, H., Vickers-Douglas, K. S., Palmer, B. A., & Lopez-Jimenez, F. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000486794 · Cited by 39 · see citing works
Treatment Selection in Depression: The Role of Clinical Judgment
Tomba, E., & Fava, G. A. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.11.003 · Cited by 35 · see citing works
Self-citationInternational Task Force on Benzodiazepines
Balon, R., Chouinard, G., Cosci, F., Dubovsky, S. L., Fava, G. A., Freire, R. C., Greenblatt, D. J., Krystal, J. H., Nardi, A. E., Rickels, K., et al. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000489538 · Cited by 35 · see citing works
Self-citationBenzodiazepines and anxiety sensitivity in panic disorder
Fava, G. A., Grandi, S., Belluardo, P., Savron, G., Raffi, A. R., Conti, S., & Saviotti, F. M. (1994) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(94)90118-x · Cited by 32 · see citing works
Self-citationFux, M., Taub, M., & Zohar, J. (1993) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1993.tb03448.x · Cited by 32 · see citing works
Khan, A., Musgnung, J., Ramey, T., Messig, M., Buckley, G., & Ninan, P. T. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000100 · Cited by 30 · see citing works
Effect of Abrupt Discontinuation of Antidepressants in Critically Ill Hospitalized Adults
Bainum, T. B., Fike, D. S., Mechelay, D., & Haase, K. K. (2017) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1992 · Cited by 28 · see citing works
The hidden costs of financial conflicts of interest in medicine
Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000442694 · Cited by 25 · see citing works
Self-citationThe mental health clinic: a new model
Fava, G. A., PARK, S. K., & Dubovsky, S. L. (2008) · World Psychiatry · doi:10.1002/j.2051-5545.2008.tb00192.x · Cited by 22 · see citing works
Self-citationMania associated with venlafaxine discontinuation
Fava, G. A., & Mangelli, L. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003274 · Cited by 21 · see citing works
Self-citationGallagher, J. C., Strzinek, R. A., Cheng, R.-F. J., Ausmanas, M. K., Astl, D., & Seljan, P. (2011) · Journal of Women s Health · doi:10.1089/jwh.2011.2764 · Cited by 21 · see citing works
The Prescription of Benzodiazepines for Panic Disorder
Nardi, A. E., Cosci, F., Balon, R., Weintraub, S. J., Freire, R. C. R., Krystal, J. H., Roth, T. G., Silberman, E. K., Sonino, N., Fava, G. A., et al. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000908 · Cited by 20 · see citing works
Self-citationFava, G. A. (1998) · Psychotherapy and Psychosomatics · doi:10.1159/000012280 · Cited by 16 · see citing works
Self-citationPsychotherapeutic Strategies in the Treatment of Psychophysiologic Disorders
Kellner, R. (2010) · Psychotherapy and Psychosomatics · doi:10.1159/000287376 · Cited by 14 · see citing works
What psychologists need to know about psychotropic medications
Tomba, E., Guidi, J., & Fava, G. A. (2018) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.2154 · Cited by 11 · see citing works
Self-citationShould benzodiazepines be avoided?
Jørgensen, M. B., & Osler, M. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12943 · Cited by 6 · see citing works
Flagged first, then by citations
1 of the 56 references couldn’t be matched to a known paper.
Research works printed but not linked: 25
- Scholten WD, Batelaan NM, van Oppen P, Smit JH, Hoogendoorn AW, van Megen HJGM, Cath DC, van Balkom AJLM: The ef- ficacy of a group CBT relapse prevention pro- gram for remitted anxiety disorder patients who discontinue antidepressant medication: a randomized controlled trial. Psychother Psychosom 2018; 87: 240-242.
- Fava GA, Rafanelli C, Grandi S, Conti S, Bel- luardo P: Prevention of recurrent depression with cognitive behavioral therapy. Arch Gen Psychiatry 1998; 55: 816-820.
- Fava GA, Grandi S, Belluardo P, Savron G, Raffi AR, Conti S, Saviotti FM: Benzodiaze- pines and anxiety sensitivity in panic disor- der. Prog Neuropsychopharmacol Biol Psy- chiatry 1994; 18: 1163-1168.
- Belaise C, Gatti A, Chouinard VA, Chouinard G: Patient online report of selective serotonin reuptake inhibitor (SSRI) induced persistent postwithdrawal anxiety and mood disorders. Psychother Psychosom 2012; 81: 386-388.
- Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J: Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitors discontinuation. Psychother Psychosom 2018; 87: 195-203.
- Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA: The safety, tolerability and risks associated with the use of newer generation antidepressant drugs. Psychother Psychosom 2016; 85: 270-288.
- Maslej MM, Bolker BM, Russell MJ, Eaton K, Durisko Z, Hollon SD, Swanson GM, Thom- son JA, Mulsant BH, Andrews PW: The mor- tality and myocardial effects of antidepres- sants are moderated by pre-existing cardio- vascular disease. Psychother Psychosom 2017; 86: 268-282.
- Huang WS, Bai YM, Hsu JW, Huang KL, Tsai CF, Su TP, Li CT, Lin WC, Tsai SJ, Pan TL, Chen TJ, Chen MH: Use of proton pump in- hibitors and risk of major depressive disorder. Psychother Psychosom 2018; 87: 62-64.
- Huijbregts KM, Hoogendoorn AW, Slottje P, van Balkom AJLM, Batelaan NM: Long-term and short-term antidepressant use in general practice. Psychother Psychosom 2017; 86: 362-369.
- Warner CH, Bobo W, Warner C, Reid S, Ra- chal J: Antidepressant discontinuation syn- drome. Am Fam Physician 2006; 74: 449-456.
- Fava GA, Tomba E: Treatment of comorbid anxiety disorders and depression; in Em- melkamp P, Ehring T (eds): The Wiley Hand- book of Anxiety Disorders. Chichester, Wi- ley, 2014, pp 1165-1182.
- Cosci F, Chouinard G, Chouinard V-A, Fava GA: The Diagnostic Clinical Interview for Drug Withdrawal 1 (DID-W1) -new symp- toms of selective serotonin reuptake inhibi- tors (SSRI) or serotonin noradrenaline reup- take inhibitors (SNRI): inter-rater reliability. Riv Psichiatr 2018; 53: 95-99.
- Chouinard G, Samaha AN, Chouinard V-A, Peretti C-S, Kanahara N, Takase M, Iyo M: Antipsychotic-induced dopamine supersen- sitivity psychosis. Psychother Psychosom 2017; 86: 189-219.
- Pollack MH, Van Ameringen M, Simon N, Worthinton JW, Hoge EA, Keshaviah A, Stein MB: A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psy- chiatry 2014; 171: 44-53.
- Cloos JM, Bocquet V, Rolland-Portal I, Koch P, Chouinard G: Hypnotics and triazoloben- zodiazepines -best predictors of high-dose benzodiazepine use. Psychother Psychosom 2015; 84: 273-283.
- Fava GA, Sonino N: Depression associated with medical illness. CNS Drugs 1996; 5: 175- 189.
- Spina E, Trifirò G, Caraci F: Clinically signif- icant drug interactions with newer antide- pressants. CNS Drugs 2012; 26: 39-67.
- Fava GA, Grandi S, Rafanelli C, Fabbri S, Ca- zzaro M: Explanatory therapy in hypochon- driasis. J Clin Psychiatry 2000; 61: 317-322.
- Marks IM: Fears, Phobias and Rituals. New York, Oxford University Press, 1987.
- Sonino N, Fava GA: A simple instrument for assessing stress in clinical practice. Postgrad Med J 1998; 74: 408-410.
- Offidani E, Guidi J, Tomba E, Fava GA: Effi- cacy and tolerability of benzodiazepines ver- sus antidepressants in anxiety disorders. Psy- chother Psychosom 2013; 82: 355-362.
- Benasi G, Guidi J, Offidani E, Balon R, Rickels K, Fava GA: Benzodiazepines as a monother- apy in depressive disorders: a systematic re- view. Psychother Psychosom 2018; 87: 65-74.
- Jorgensen MB, Osler M: Should benzodiaze- pines be avoided? Acta Psychiatr Scand 2018; 138: 89-90.
- Tomba E, Guidi J, Fava GA: What psycholo- gists need to know about psychotropic medi- cations. Clin Psychol Psychother 2018; 25: 181-187.
- Baldessarini RJ, Ghaemi SN, Viguera AC: Tolerance in antidepressant treatment. Psy- chother Psychosom 2002; 71: 177-179.
Cited by
Sorted by citations
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265 · see citing works
Clinical characterization of allostatic overload
Fava, G. A., McEwen, B. S., Guidi, J., Gostoli, S., Offidani, E., & Sonino, N. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.05.028 · Cited by 265 · see citing works
Self-citationGuidi, J., & Fava, G. A. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3650 · Cited by 155 · see citing works
Self-citationFava, G. A., & Guidi, J. (2020) · World Psychiatry · doi:10.1002/wps.20698 · Cited by 143 · see citing works
Self-citationGreenway, K. T., Garel, N., Jerome, L., & Feduccia, A. A. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1772054 · Cited by 94 · see citing works
Fava, G. A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320970325 · Cited by 84 · see citing works
Self-citationIatrogenic Factors in Psychopathology
Fava, G. A., & Rafanelli, C. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000500151 · Cited by 82 · see citing works
Self-citationProdromal Symptoms in Depression: A Systematic Review
Benasi, G., Fava, G. A., & Guidi, J. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000517953 · Cited by 74 · see citing works
Self-citationHengartner, M. P., Schulthess, L., Sorensen, A., & Framer, A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320980573 · Cited by 74 · see citing works
Understanding and Managing Withdrawal Syndromes After Discontinuation of Antidepressant Drugs
Fava, G. A., & Cosci, F. (2019) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19com12794 · Cited by 69 · see citing works
Self-citationDunlop, B. W., LoParo, D., Kinkead, B. L., Mletzko, T., Cole, S. P., Nemeroff, C. B., Mayberg, H. S., & Craighead, W. E. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18091075 · Cited by 65 · see citing works
When Anxiety and Depression Coexist: The Role of Differential Diagnosis Using Clinimetric Criteria
Cosci, F., & Fava, G. A. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000517518 · Cited by 63 · see citing works
Self-citationEffects of Treatment Discontinuation in Clinical Psychopharmacology
Baldessarini, R. J., & Tondo, L. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000497334 · Cited by 52 · see citing works
Groot, P. C., & van Os, J. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320932452 · Cited by 49 · see citing works
von Brachel, R., Hirschfeld, G. H. F., Berner, A., Willutzki, U., Teismann, T., Cwik, J. C., Velten, J., Schulte, D., & Margraf, J. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000500188 · Cited by 49 · see citing works
Kuhlmann, S. L., Arolt, V., Haverkamp, W., Martus, P., Ströhle, A., Waltenberger, J. L., Rieckmann, N., & Müller‐Nordhorn, J. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000501502 · Cited by 49 · see citing works
Antidepressant withdrawal – the tide is finally turning
Hengartner, M. P., Davies, J., & Read, J. (2020) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796019000465 · Cited by 48 · see citing works
The Deceptive Manifestations of Treatment Resistance in Depression: A New Look at the Problem
Fava, G. A., Cosci, F., Guidi, J., & Rafanelli, C. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000507227 · Cited by 48 · see citing works
Self-citationThe emerging role of euthymia in psychotherapy research and practice
Guidi, J., & Fava, G. A. (2020) · Clinical Psychology Review · doi:10.1016/j.cpr.2020.101941 · Cited by 40 · see citing works
Self-citationRécalt, A. M., & Cohen, D. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000496734 · Cited by 38 · see citing works
Chiappini, S., Vickers‐Smith, R., Guirguis, A., Corkery, J., Martinotti, G., & Schifano, F. (2022) · Pharmaceuticals · doi:10.3390/ph15050565 · Cited by 34 · see citing works
Cohen, D., & Recalt, A. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000496733 · Cited by 28 · see citing works
Antidepressant discontinuation syndrome: A state-of-the-art clinical review
Fornaro, M., Cattaneo, C. I., Berardis, D. D., Ressico, F. V., Martinotti, G., & Vieta, E. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.10.005 · Cited by 29 · see citing works
Cosci, F., Mansueto, G., & Fava, G. A. (2020) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2020.1779308 · Cited by 26 · see citing works
Self-citationOutcomes of hyperbolic tapering of antidepressants
van Os, J., & Groot, P. C. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231171518 · Cited by 22 · see citing works
Aisha, Raza, M. A., Sumrra, S. H., Javed, K., Saqib, Z., Maurin, J. K., & Budzianowski, A. (2020) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2020.128609 · Cited by 24 · see citing works
The need for antidepressant withdrawal support services: Recommendations from 708 patients
Read, J., Lewis, S., Horowitz, M. A., & Moncrieff, J. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115303 · Cited by 24 · see citing works
Psychotherapy in recurrent depression: efficacy, pitfalls, and recommendations
Cosci, F., Guidi, J., Mansueto, G., & Fava, G. A. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1804870 · Cited by 26 · see citing works
Self-citationSørensen, A., Jørgensen, K. J., & Munkholm, K. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.08.011 · Cited by 22 · see citing works
Conceptual and Clinical Innovations of Well-being Therapy
Guidi, J., & Fava, G. A. (2021) · International Journal of Cognitive Therapy · doi:10.1007/s41811-021-00101-1 · Cited by 21 · see citing works
Self-citationScholten, W., Batelaan, N., & Van Balkom, A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320933404 · Cited by 17 · see citing works
Brouwer, M. E., Molenaar, N. M., Burger, H., Williams, A. D., Albers, C. J., den Berg, M. P. L., & Bockting, C. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.574357 · Cited by 15 · see citing works
SSRI withdrawal syndrome in children and adolescents: a narrative literature review
Khan, Y. S., Khoodoruth, M. A. S., Albobali, Y., & Haddad, P. M. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2224557 · Cited by 12 · see citing works
Interventions to help patients withdraw from depression drugs: A systematic review
Gøtzsche, P. C., & Demasi, M. (2023) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-230011 · Cited by 12 · see citing works
Addressing Clinical Challenges of Antidepressant Discontinuation
Fava, G. A., & Cosci, F. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.18121419 · Cited by 10 · see citing works
Self-citationNardi, A. E., & Quagliato, L. A. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000524730 · Cited by 10 · see citing works
A Literature Review on Holistic Well-Being and Dopamine Fasting: An Integrated Approach
Desai, D. H., Patel, J., Saiyed, F., Upadhyay, H., Kariya, P., & Patel, J. (2024) · Cureus · doi:10.7759/cureus.61643 · Cited by 9 · see citing works
Patacchini, A., & Cosci, F. (2021) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-200074 · Cited by 9 · see citing works
The Emerging Role of Clinical Pharmacopsychology
Cosci, F., Guidi, J., Tomba, E., & Fava, G. A. (2019) · Clinical Psychology in Europe · doi:10.32872/cpe.v1i2.32158 · Cited by 8 · see citing works
Self-citationRennwald, A., & Hengartner, M. P. (2025) · Epidemiology and Psychiatric Sciences · doi:10.1017/s204579602500023x · Cited by 8 · see citing works
“Our review’s main finding thus reflects the poor recognition and insufficient consideration of PAWS in both clinical research and practice (Cosci et al. , 2024; Fava and Belaise, 2018;HorowitzandDavies,2025;Read etal.”
Coe, A., Abid, N., & Kaylor‐Hughes, C. (2024) · Australian Journal of Primary Health · doi:10.1071/py23046 · Cited by 8 · see citing works
Cosci, F., Chouinard, V., & Chouinard, G. (2023) · Psychotherapy and Psychosomatics · doi:10.1159/000530692 · Cited by 7 · see citing works
Maladaptive or misunderstood? Dopamine fasting as a potential intervention for behavioral addiction
Fei, Y. Y., Johnson, P. A., Omran, N. A. L., Mardon, A. A., & Johnson, J. C. (2021) · Lifestyle Medicine · doi:10.1002/lim2.54 · Cited by 6 · see citing works
Wang, Q., Cheng, L., Wu, B.-Y., Xu, P., Qiu, H.-Y., Wang, B., Yan, X.-J., & Chen, S. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1063722 · Cited by 8 · see citing works
Carlo, V. D., Grancini, B. M., Vismara, M. E. M., Benatti, B., Arici, C., Cremaschi, L., Cirnigliaro, G., Degoni, L., Oldani, L., Palazzo, C., et al. (2019) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2695 · Cited by 6 · see citing works
Glanger, M. R., Peterson, G. M., & Abraham, A. (2021) · Internal Medicine Journal · doi:10.1111/imj.15320 · Cited by 5 · see citing works
Antidepressant Tapering Is Not Routine But Could Be
Phelps, J. R., Nguyen, J., & Pipitone, O. (2023) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2022.220239r1 · Cited by 5 · see citing works
Well-Being Therapy in Anxiety Disorders
Cosci, F. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9705-0_24 · Cited by 5 · see citing works
Bschor, T., Bonnet, U., Pitzer, M., Baethge, C., Lieb, K., Gertz, H.-J., & Müller-Oerlinghausen, B. (2022) · PubMed · doi:10.1007/s00115-021-01243-5 · Cited by 4 · see citing works
Dependence on newer generation antidepressants
Vaaler, A. (2022) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.22.0339 · Cited by 4 · see citing works
Fava, G. A., Cosci, F., Montiel, C. B., & Tomba, E. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000495967 · Cited by 4 · see citing works
Self-citationGeneralization and enhancement of the effects of an active placebo nasal spray on sadness
Wilhelm, M., Fischer, S. M., Rief, W., Fiorio, M., & Barbiani, D. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.10.045 · Cited by 3 · see citing works
The Clinical Meaning of Withdrawal with Antidepressant Drugs
Fava, G. A. (2024) · Psychotherapy and Psychosomatics · doi:10.1159/000540033 · Cited by 3 · see citing works
Self-citationWang, M., Zhao, X., Wang, H., Liu, J., Ren, J., Gao, M., Cheng, F.-E., Chen, P., Yao, W., Cao, Y., et al. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.150704 · Cited by 2 · see citing works
Sun, F., Long, A., Wu, M., Chiu, N., Hung, C., & Tseng, Y. S. (2021) · Journal of the American Psychiatric Nurses Association · doi:10.1177/10783903211039886 · Cited by 2 · see citing works
SOP Absetzen von Antidepressiva
Bschor, T., & Kleemann, A. M. (2022) · PSYCH up2date · doi:10.1055/a-1673-8792 · Cited by 2 · see citing works
Guidi, J., & Cosci, F. (2023) · Psychotherapy and Psychosomatics · doi:10.1159/000528717 · Cited by 2 · see citing works
Vukas, J., Brišnik, V., Sanftenberg, L., Henningsen, P., Gensichen, J. S., & Dreischulte, T. (2025) · European Journal of General Practice · doi:10.1080/13814788.2025.2531879 · Cited by 1 · see citing works
Moradveisi, L., Huibers, M. J. H., & Arntz, A. R. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-07220-5 · Cited by 1 · see citing works
Assessing Suicide Risk in Airline Pilots With Major Depression
Vuorio, A. F., Suhonen-Malm, A.-S., Budowle, B., Gray, A., Gordon, S., & Bor, R. J. (2026) · Aviation Psychology and Applied Human Factors · doi:10.1027/2192-0923/a000313 · Cited by 1 · see citing works
Biogenetic etiologies of OCD: Review and recommendations for clinicians
Schultz, W. (2019) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2019.100451 · Cited by 1 · see citing works
Fava, G. A., & Guidi, J. (2020) · Ärztliche Psychotherapie · doi:10.21706/aep-15-3-149 · Cited by 1 · see citing works
Self-citationKostic, M. V., Vuković, O., Munjiza, A., Pešić, D., Vezmar, M., Podgorac, A., Ranđelović, D., Mandić-Maravić, V., Todorović, D., Jakovljević, A., et al. (2020) · Psihijatrija danas · doi:10.5937/psihdan2001025k
Two Perspectives of Mental Distress
Cornelius, J. T. (2021) · Psychoanalytic Inquiry · doi:10.1080/07351690.2021.1983407
Introduction to Deprescribing Psychiatric Medications
(2024) · Wiley eBooks · doi:10.1002/9781394291052.mdg001
Safe Deprescribing of Antidepressants
(2024) · Wiley eBooks · doi:10.1002/9781394291052.mdg002
Well-Being Therapy for Depression
Romanazzo, S., & Cosci, F. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-981-97-4402-2_14
Zolotareva, A. A. (2025) · Journal of Modern Foreign Psychology · doi:10.17759/jmfp.2024130408
Premier module psychothérapeutique
Fava, G. A., & Peretti, C.-S. (2024) · Elsevier eBooks · doi:10.1016/b978-2-294-77932-9.00009-1
Self-citationDeuxième module psychothérapeutique
Fava, G. A., & Peretti, C.-S. (2024) · Elsevier eBooks · doi:10.1016/b978-2-294-77932-9.00010-8
Self-citationComprendre la physiopathologie des syndromes de sevrage
Fava, G. A., & Peretti, C.-S. (2024) · Elsevier eBooks · doi:10.1016/b978-2-294-77932-9.00004-2
Self-citationLa décision d’arrêter de prendre des antidépresseurs
Fava, G. A., & Peretti, C.-S. (2024) · Elsevier eBooks · doi:10.1016/b978-2-294-77932-9.00005-4
Self-citationStratégies et options pharmacologiques
Fava, G. A., & Peretti, C.-S. (2024) · Elsevier eBooks · doi:10.1016/b978-2-294-77932-9.00008-x
Self-citationPrévention de la dépendance et de la symptomatologie du sevrage dus aux traitements antidépresseurs
Fava, G. A., & Peretti, C.-S. (2024) · Elsevier eBooks · doi:10.1016/b978-2-294-77932-9.00012-1
Self-citationSong, Y., Zuo, F., Gu, R., Zhang, Y., Ye, S., & Xu, T. (2025) · ACS Applied Polymer Materials · doi:10.1021/acsapm.5c02914
Rennwald, A., Horowitz, M. A., Senn, O., Neuner-Jehle, S., & Hengartner, M. P. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261492597
- Authors
- Fava, G. A., & Belaise, C.
- Affiliations
- University at Buffalo, State University of New York (US)
- University of Bologna (IT)
- ORCID
- Fava, Giovanni A.
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2018
- Volume
- 87
- Issue
- 5
- Pages
- 257-267
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2889187894
- Cited by
- 77
- References
- 56
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 13 · 2023: 7 · 2022: 9 · 2021: 8 · 2020: 17 · 2019: 15
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Social Sciences › Psychology › Social Psychology › Mental Health Treatment and Access
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- antidepressant discontinuation, depression treatment, clinical experience
- MeSH terms
- Antidepressive Agents, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
